The in vitro activities of four new beta-lactam antimicrobial agents (moxalactam, cefotaxime, cefoperazone, and piperacillin) and the aminoglycosides against 744 recent clinical isolates of facultative gram-negative bacilli were compared simultaneously by the agar dilution method. The major in vitro difference of these newer beta-lactam compounds appeared to be their antipseudomonal activity; cefoperazone was the most active, whereas cefotaxime had the least potency. The aminoglycosides, however, had the most effective in vitro activity on a weight basis against Pseudomonas aeruginosa.
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Moxalactam, cefotaxime, cefoperazone, and piperacillin are four new beta-lactam antibiotics developed in the past few years with a wide spectrum of activity against gram-negative bacilli. Preliminary testing has suggested that these new beta-lactam antibiotics possess a broad spectrum of in vitro activity against most clinically important gram-negative bacteria, including Pseudomonas aeruginosa, Klebsiella pneumoniae, Serratia marcescens, Enterobacter species, and Bacteroides fragilis. Indeed, the potential clinical usefulness of these new betalactam antibiotics appears to be related to a wider spectrum of activity than other beta-lactam antibiotics and lower toxicity than the aminoglycoside drugs. Several previous in vitro studies (1, 5, 8, 10, 11, 14) have compared each of these newly developed compounds individually with the older beta-lactam antibiotics, but there is relatively little information on the comparative in vitro activity of all four drugs tested simultaneously against recent clinical isolates of gram-negative bacilli (2, 6, 9, 15 the most active antimicrobial agents tested against Acinetobacter calcoaceticus. This study demonstrates that moxalactam, cefotaxime, cefoperazone, and piperacillin are highly active against most clinically important bacterial strains isolated from patients at a large university hospital. Moxalactam, cefotaxime, and cefoperazone inhibited 90% or more of the strains of E. coli, K. pneumoniae, Enterobacter species, S. marcescens, Proteus species, and C. freundii at 16 ,ug/ml, and most were inhibited by 8 ,tg/ml. Except for E. coli, piperacillin inhibited 90% of these same organisms at 64 ,ug/ ml. Moxalactam was the most active of the betalactam antibiotics against the Enterobacteriaceae and inhibited most strains at 0.5 ,g/ml. In general, except for P. aeruginosa, moxalactam's in vitro activity was comparable to that of the aminoglycosides.
P. aeruginosa isolates were less susceptible to the beta-lactam antibiotics. Indeed, cefotaxime had relatively little antipseudomonal activity and inhibited only 5% of the P. aeruginosa isolates at 32 ,ug/ml. These results are somewhat surprising in view of cefotaxime's favorable antipseudomonal activity reported by others (2, 6, 10, 15) . Regional variations in the susceptibility patterns of bacterial isolates as well as the recovery of many of our P. aeruginosa isolates from a large population of immunocompromised patients commonly infected with more resistant organisms may account for some of these differences. Cefoperazone, a cephalosporin analog of piperacllin, was twofold more active than moxalactam or piperacillin for P. aeruginosa and was the most active beta-lactam agent for P. aeruginosa. Similar results favoring cefoperazone over moxalactam, cefotaxime, and piperacillin for P. aeruginosa have been reported by Neu et al. (10) and Hall et al. (6) . However, the aminoglycosides were still 4-to 8-fold more active than cefoperazone for the P. aeruginosa isolates in our study.
We did not perforn comparative susceptibility tests with gram-positive organisms and anaerobes in this study, but other investigators (6, 8, 10) have shown that Staphylococcus aureus and facultative streptococci usually require MICs of 2 to 8 ,ug of moxalactam, cefotaxime, and cefoperazone per ml, and that Streptococcus faecalis isolates are invariably resistant to these antimicrobial agents (MIC > 32 ,ig/ml). In contrast, piperacillin usually inhibits most S. faecalis strains but lacks activity against Staphylococcus aureus (14) . Previous comparative anaerobic susceptibility tests suggest that moxalactam's activity against B. fragilis is superior to that of cefotaxime, cefoperazone, cefoxitin, and other cephalosporins (2) .
In summary, our results show that cefoperazone was the most active of the beta-lactam antibiotics against P. aeruginosa. Moxalactam had the greatest activity on a weight basis against the Enterobacteriaceae and was comparable to the aminoglycosides against these same organisms. The significance of these relative differences of in vitro activity, however, must await carefully conducted comparative clinical trials.
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